Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation

Pharmaceutical Research

Volumn 16, Issue 1, 1999, Pages 16-23

  Gudmundsson, Olafur S ^a,b   Nimkar, Kalpana ^a   Gangwar, Sanjeev ^a,c   Siahaan, Teruna ^a   Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Coulter Pharm Inc ^*  (United States)

Author keywords

Caco 2 cells; Chemical and enzymatic stability; Esterase sensitive prodrugs; Membrane permeability; Opioid peptides; Peptide delivery

Indexed keywords

OPIATE PEPTIDE; PEPTIDASE; PHENYLPROPIONIC ACID DERIVATIVE; PRODRUG;

ARTICLE; CELL MEMBRANE PERMEABILITY; DERIVATIZATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME STABILITY; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGEN BOND; LIVER HOMOGENATE; MONOLAYER CULTURE; PRIORITY JOURNAL;

ANIMALS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHEMISTRY, PHYSICAL; ENDORPHINS; ENKEPHALIN, LEUCINE; ENKEPHALIN, LEUCINE-2-ALANINE; ENZYME STABILITY; HUMANS; PEPTIDES, CYCLIC; PHENYLPROPIONATES; PRODRUGS; PROTEIN CONFORMATION; RATS;

EID: 0032930316     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018802324759     Document Type: Article

References (27)

1. G. M. Pauletti, S. Gangwar, G. T. Knipp, M. M. Nerurkar, F. W. Okumu, K. Tamura, T. J. Siahaan, and R. T. Borchardt. Structural requirement for intestinal absorption of peptide drugs. J. Contr. Rel. 41:3-17 (1996).
2. G. M. Pauletti, S. Gangwar, T. J. Siahaan, J. Aube, and R. T. Borchardt. Improvement of oral bioavailability: Peptidomimetics and prodrug strategies. Adv. Drug Deliv. Rev. 27:235-256 (1997).
3. P. W. Schiller. Development of receptor-selective opioide peptide analogs as pharmacological tools and as potential drugs. Handbook Exp. Pharmacol. 104:681-710 (1993).
4. V. J. Hruby and C. A. Gehrig. Recent development in the design of receptor specific opioid-peptides. Med. Res. Rev. 9:343-401 (1989).
5. V. H. L. Lee. Enzymatic barriers to peptide and protein absorption. CRC Critical Reviews in Therapeutic Drug Carrier Systems 5:69-97 (1988).
6. P. B. Watkins. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27:161-170 (1997).
7. P. S. Burton, J. T. Goodwin, R. A. Conradi, N. F. H. Ho, and A. R. Hilgers. In vitro permeability of peptidomimetics: the role of polarized efflux pathways as additional barriers to absorption. Adv. Drug. Deliv. Rev. 23:143-156 (1997).
8. S. Gangwar, G. M. Pauletti, B. Wang, T. J. Siahaan, V. J. Stella, and R. T. Borchardt. Prodrug strategies to enhance the intestinal absorption of peptides. Drug Discovery Today 2:148-155 (1997).
9. S. Gangwar, G. M. Pauletti, T. J. Siahaan, V. J. Stella, and R. T. Borchardt. Synthesis of a novel esterase-sensitive cyclic prodrug of a model hexapeptide using an acyloxyalkoxy promoiety. J. Org. Chem. 62:1356-1362 (1997).
10. G. M. Pauletti, S. Gangwar, F. W. Okumu, T. J. Siahaan, V. J. Stella, and R. T. Borchardt. Esterase-sensitive cyclic prodrugs of peptides: Evaluation of an acyloxyalkoxy promoiety in a model hexapeptide. Pharm. Res. 13:1615-1623 (1996).
11. G. M. Pauletti, S. Gangwar, B. Wang, and R. T. Borchardt. Esterase-sensitive cyclic prodrugs of peptides: evaluation of a phenylpropioinc acid promoiety in a model hexapeptide. Pharm. Res. 14:11-17 (1997).
12. B. Wang, S. Gangwar, G. M. Pauletti, T. J. Siahaan, and R. T. Borchardt. Synthesis of a unique esterase-sensitive cyclic prodrug system for peptides that utilize a trimethyl-lock-facilitated lactonization reaction. J. Org. Chem. 62:1363-1367 (1997).
13. B. Wang, K. Nimkar, W. Wang, H. Zhang, D. Shan, O. S. Gudmundsson, S. Gangwar, T. J. Siahaan, and R. T. Borchardt. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using phenylpropionic acid and coumarinic acid linkers. J. Peptide Res. (in press).
14. A. Bak, T. J. Siahaan, O. S. Gudmundsson, G. J. Friis, and R. T. Borchardt. Syntheses and evaluation of the physicochemical properties of esterase sensitive cyclic prodrugs of opioid pepides containing an acyloxyalkoxy promoiety. J. Peptide Res. (in press).
15. I. J. Hidalgo, T. J. Raub, and R. T. Borchardt. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal permeability. Gastroenterology 96:736-749 (1989).
16. O. S. Gudmundsson, G. M. Pauletti, W. Wang, D. Shan, H. Zhang, B. Wang, and R. T. Borchardt. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability. Pharm. Res. 16:7-15 (1989).
17. A. Bak, O. S. Gudmundsson, G. J. Friis, T. J. Sihaan, and R. T. Borchardt. Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of their chemical and enzymatic stability as well as the their transport properties across Caco-2 cell monolayers. Pharm. Res. 16:24-29 (1999).
18. O. S. Gudmundsson, S. D. S. Jois, D. G. Vander Velde, T. J. Siahaan, B. Wang, and R. T. Borchardt. The effect of conformation on the membrane permeability of coumarinic acid- and phenylpropionic acid-based cyclic prodrugs of opioid peptides. J. Peptide Res. (in press).
19. P. De-Montigny, C. M. Riley, L. A. Sternson, and J. F. Stobaugh. Fluorogenic derivatization of peptides with naphthalene-2,3-dicarboxaldehyde/cyanide: optimization of yield and application in the determination of leucine-enkephalin spiked human plasma samples. J. Pharm. Biomed. Anal 8:419-429 (1990).
20. M. Mifune, D. K. Krehbiel, J. F. Stobaugh, and C. M. Riley. Multi-dimensional high performance liquid chromatography of opioid peptides following precolumn derivatization with naphthalene-2,3-dicarboxaldehyde in the presence of cyanide ion. Preliminary results on the determination of leucine- and methionine-enkephalin - like fluorescence in the striatum region of the rat brain. J. Chromatogr. 496:55-70 (1989).
21. H. Lennernas, K. Palm, U. Fagerholm, and P. Artursson. Correlation between paracellular and transcellular drug permeability in the human jejunum and Caco-2 monolayers. Int. J. Pharm. 127:103-107 (1996).
22. C. A. Bailey, P. Bryla, and A. W. Malick. The use of the intestinal epithelial cell model, Caco-2, in pharmaceutical development. Adv. Drug Deliv. Rev. 22:85-103 (1996).
23. J. Hunter and B. H. Hirst. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting drug absorption. Adv. Drug Deliv. Rev. 25:129-157 (1997).
24. 24. M. Sudoh, G. M. Pauletti, W. Yao, P. A. Sprengler, A. B. Smith III, R. Hirschmann, and R. T. Borchardt. Transport characteristics of peptidomimetics. Effect of pyrolinone bioisostere on transport across Caco-2 cell monolayers. Pharm. Res. 15:719-725 (1998).
25. O. S. Gudmundsson, D. G. Vander Velde, S. D. S. Jois, A. Bak, T. J. Siahaan, and R. T Borchardt. The effect of conformation on the membrane permeability of acyloxyalkoxy-based cyclic prodrugs of opioid peptides. J. Peptide Res. (in press).
26. M. Ruwart. Approaches to modulating liver transport of peptide drugs, in M. D. Taylor and G. L. Amidon (eds.), Peptide-based drug design: controlling transport and metabolism, American Chemical Society. Washington DC, 1995, pp. 249-262.
27. D. L. Marks, G. J. Gores, and N. F. LaRusso, Hepatic processing of peptides, in M. D. Taylor and G. L. Amidon (eds.), Peptide-based drug design: controlling transport and metabolism, American Chemical Society. Washington, DC, 1995, pp. 222-248.